US20020012713A1 - Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same - Google Patents

Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same Download PDF

Info

Publication number
US20020012713A1
US20020012713A1 US09/853,695 US85369501A US2002012713A1 US 20020012713 A1 US20020012713 A1 US 20020012713A1 US 85369501 A US85369501 A US 85369501A US 2002012713 A1 US2002012713 A1 US 2002012713A1
Authority
US
United States
Prior art keywords
extract
methylglucamine
water
ginkgo biloba
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/853,695
Other versions
US6447819B2 (en
Inventor
Silvano Paracchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Linnea SA
Original Assignee
Linnea SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linnea SA filed Critical Linnea SA
Assigned to LINNEA SA reassignment LINNEA SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PARACCHINI, SILVANO
Publication of US20020012713A1 publication Critical patent/US20020012713A1/en
Application granted granted Critical
Publication of US6447819B2 publication Critical patent/US6447819B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a water-soluble complex of an extract of Ginkgo biloba, to a process for the preparation thereof and to a composition comprising the same.
  • the present invention relates to a water-soluble complex of an extract of Ginkgo biloba with N-methylglucamine.
  • Extracts of Ginkgo biloba have been studied for years both from a chemical point of view and from a pharmacological and clinical point of view since they comprise compounds endowed with cerebral and peripheral vasomotor activity.
  • dry extracts used in pharmaceuticals have the following composition:
  • heterosides (expressed as flavone glycosides, consisting mainly of quercetin-3-O-(6′′′-trans-p-cumaroyl-2′′-glucosyl)rhamnoside and kaempferol and isorhamnetin-3-O-(6′′′-trans-p-cumaroyl-2′′-glucosyl)rhamnoside);
  • proanthocyanidins consisting of mixtures of anthocyanidins and delphinidin dimers and polymers
  • patent application WO 00/01397 discloses a water-soluble dry extract obtained from an hydroalcoholic extract of Ginkgo biloba leaves by means of targeted ultrafiltration.
  • Patent application FR-A-2 755 015 discloses an extract of flavonoids from Ginkgo biloba leaves, with a low content of other components, which has anti-elastase and anti-inflammatory activity on human gums.
  • the said document also describes a pharmaceutical composition containing the abovementioned extract for the topical treatment of the abovementioned complaints.
  • the pharmaceutical compositions can also be in liquid form.
  • the document never mentions aqueous solutions since the abovementioned extract is not water-soluble.
  • water-soluble means a solubility in water of at least 1% (w/v).
  • composition of the extract of Ginkgo biloba leaves reacted with N-methylglucamine is preferably as follows:
  • flavone glycosides 22-45% (w/w),
  • proanthocyanidins 3-8% (w/w).
  • the amount of extract reacted on a dry-weight basis is preferably of about 1.5-3.0 times and even more preferably to twice the weight of the N-methylglucamine.
  • the said alcoholic solution is typically a solution of a saturated aliphatic alcohol having of from 1 to 4 carbon atoms and having a linear or branched chain, such as, for example, methanol, ethanol or isobutanol.
  • step a) is carried out at a temperature of between 0C and the boiling point of the reaction mixture. Even more preferably, this temperature is between 20 and 70° C.
  • Step c) is typically carried out by evaporating off the solvent under reduced pressure.
  • composition of the thus obtained water-soluble complex is advantageously as follows:
  • flavone glycosides 15-30% (w/w),
  • ginkgolides 0.1-7% (w/w),
  • bilobalide 0-2% (w/w),
  • proanthocyanidins 1-2% (w/w)
  • N-methylglucamine 32-34% (w/w),
  • water-soluble inert plant matter 25-51.9% (w/w).
  • composition comprising a water-soluble complex of N-methylglucamine with an extract of Ginkgo biloba leaves, characterized in that the said complex is rich in flavonoids and has a low content of other components.
  • the said complex typically has a water solubility of between 1 and 30% (w/v), and even more typically the said solubility is of from 3 to 10% (w/v).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Psychology (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicinal Preparation (AREA)

Abstract

A water-soluble complex of N-methylglucamine with an extract of Ginkgo biloba leaves, process for the preparation thereof and composition comprising the same.

Description

  • This application is based on European Patent Application No. 00202088.1 filed on Jun. 16, 2000, the content of which is incorporated hereinto by reference. [0001]
  • The present invention relates to a water-soluble complex of an extract of Ginkgo biloba, to a process for the preparation thereof and to a composition comprising the same. [0002]
  • More particularly, the present invention relates to a water-soluble complex of an extract of Ginkgo biloba with N-methylglucamine. [0003]
  • It is known that the leaves of Ginkgo biloba contain a host of heterogeneous substances formed of both liposoluble and water-soluble compounds. [0004]
  • Extracts of Ginkgo biloba have been studied for years both from a chemical point of view and from a pharmacological and clinical point of view since they comprise compounds endowed with cerebral and peripheral vasomotor activity. [0005]
  • In approximate terms, the dry extracts used in pharmaceuticals have the following composition: [0006]
  • about 24% w/w of heterosides (expressed as flavone glycosides, consisting mainly of quercetin-3-O-(6′″-trans-p-cumaroyl-2″-glucosyl)rhamnoside and kaempferol and isorhamnetin-3-O-(6′″-trans-p-cumaroyl-2″-glucosyl)rhamnoside); [0007]
  • about 6% w/w of bilobalide and ginkgolides J, A, B and C; [0008]
  • about 34% w/w of proanthocyanidins (consisting of mixtures of anthocyanidins and delphinidin dimers and polymers); [0009]
  • the balance consisting of not yet clearly identified inert plant matter. [0010]
  • However, the abovementioned extracts are not soluble in water. [0011]
  • To overcome this drawback, patent application WO 00/01397 discloses a water-soluble dry extract obtained from an hydroalcoholic extract of Ginkgo biloba leaves by means of targeted ultrafiltration. [0012]
  • Patent application FR-A-2 755 015 discloses an extract of flavonoids from Ginkgo biloba leaves, with a low content of other components, which has anti-elastase and anti-inflammatory activity on human gums. The said document also describes a pharmaceutical composition containing the abovementioned extract for the topical treatment of the abovementioned complaints. The pharmaceutical compositions can also be in liquid form. However, the document never mentions aqueous solutions since the abovementioned extract is not water-soluble. [0013]
  • Thus, there is still a great need for an extract of Ginkgo biloba leaves which is particularly rich in flavonoids and which has a low content of other components, and which is also water-soluble. [0014]
  • In the present description and in the claims, the term “water-soluble” means a solubility in water of at least 1% (w/v). [0015]
  • It has now been found, surprisingly, that this aim can be achieved by forming a complex of an extract of Ginkgo biloba with N-methylglucamine. Indeed, it was entirely unpredictable that N-methylglucamine would interact with many of the components of the abovementioned extract which lack an acid function. [0016]
  • It is therefore a first object of the present invention to provide a water-soluble complex of N-methylglucamine with an extract of Ginkgo biloba leaves. [0017]
  • Furthermore, it is a second object of the present invention to provide a process for preparing a water-soluble complex of an extract of Ginkgo biloba leaves with N-methylglucamine, the said process comprising the steps of: [0018]
  • a) adding N-methylglucamine to an alcoholic solution of the said extract, [0019]
  • b) filtering the solid product obtained from step a), and [0020]
  • c) removing the solvent. [0021]
  • The composition of the extract of Ginkgo biloba leaves reacted with N-methylglucamine is preferably as follows: [0022]
  • flavone glycosides: 22-45% (w/w), [0023]
  • ginkgolides 0.1-12% (w/w), [0024]
  • bilobalide: 0.01-5% (w/w), [0025]
  • proanthocyanidins: 3-8% (w/w). [0026]
  • The amount of extract reacted on a dry-weight basis is preferably of about 1.5-3.0 times and even more preferably to twice the weight of the N-methylglucamine. [0027]
  • The said alcoholic solution is typically a solution of a saturated aliphatic alcohol having of from 1 to 4 carbon atoms and having a linear or branched chain, such as, for example, methanol, ethanol or isobutanol. [0028]
  • Preferably, step a) is carried out at a temperature of between 0C and the boiling point of the reaction mixture. Even more preferably, this temperature is between 20 and 70° C. [0029]
  • Step c) is typically carried out by evaporating off the solvent under reduced pressure. [0030]
  • The composition of the thus obtained water-soluble complex is advantageously as follows: [0031]
  • flavone glycosides: 15-30% (w/w), [0032]
  • ginkgolides: 0.1-7% (w/w), [0033]
  • bilobalide: 0-2% (w/w), [0034]
  • proanthocyanidins: 1-2% (w/w) [0035]
  • N-methylglucamine: 32-34% (w/w), [0036]
  • water-soluble inert plant matter: 25-51.9% (w/w). [0037]
  • Finally, it is a third object of the present invention to provide a composition comprising a water-soluble complex of N-methylglucamine with an extract of Ginkgo biloba leaves, characterized in that the said complex is rich in flavonoids and has a low content of other components. [0038]
  • The said complex typically has a water solubility of between 1 and 30% (w/v), and even more typically the said solubility is of from 3 to 10% (w/v).[0039]
  • The examples which follow intend to illustrate the present invention without, however, limiting it in any way. [0040]
  • EXAMPLE 1 Preparation of the Starting Extracts
  • The extracts of Ginkgo biloba leaves used in Examples 2 to 7 had the compositions indicated in Table 1 and were prepared as follows: [0041]
  • a) Extracts 564, 597 and 564a [0042]
  • Dried Ginkgo biloba leaves were extracted with aqueous 60% acetone at 50-60° C. The thus obtained solution was concentrated to give an aqueous paste, which was cooled and filtered. Butanol was added to the thus obtained paste and the organic phase was separated out and concentrated under vacuum to an aqueous residue. The aqueous residue was washed with heptane and the alkane phase was removed. The aqueous phase was treated with ethanol, filtered and finally concentrated to dryness. The dry residue was then dried to constant weight in a vacuum oven. The obtained solid product was reduced to a fine powder. [0043]
  • The various compositions of the thus obtained extracts (Table 1) reflect the diverse content of the various components in the starting leaves. [0044]
  • b) Extract 633 [0045]
  • The process was performed as in the above case, except that the aqueous residue, obtained after removing the butanol, was extracted with ethyl acetate. The organic phase, containing ginkgolides and bilobalides, was removed, while the resulting aqueous phase was treated as described above. [0046]
  • c) Extracts 632 and 640 [0047]
  • These were prepared from extract 633, which has a low content of terpenes, by means of the extemporaneous addition of a fraction enriched in ginkgolides J, A, B and C which was prepared by purifying the ethyl acetate solution removed in the process for preparing the de-terpenated extract 633. [0048]
    TABLE I
    Flavone
    Extract glycosides Ginkgolides Bilobalide Proanthocyanidins
    No % (w/w) % (w/w) % (w/w) % (w/w)
    564 28.03 4.06 3.37 4.64
    597 27.15 7.25 3.26 4.44
      564a 28.03 4.06 3.37 4.64
    632 38.17 4.3 0.28 3.22
    633 41.22 0.5 0.1 3.48
    640 36.15 8.94 0.1 3.04
  • EXAMPLE 2 Preparation of the N-methylglucamine/extract Complex (Weight Ratio 1:2)
  • A solution of extract 564 (20 g) of Table I in methanol (200 ml) was placed in a reactor equipped with a reflux condenser and a stirrer. The mixture was kept stirring until the solid extract had fully dissolved. This solution was then heated to 60° C and N-methylglucamine (10 g) was added thereto. The mixture was maintained at reflux for 15 minutes with stirring, cooled to 30° C. and filtered. The thus obtained solution was concentrated under reduced pressure and at a temperature of not more than 50° C. The resulting solid residue was ground and brought to dryness under reduced pressure and at a temperature of not more than 70° C. [0049]
  • 26.74 g of the desired product were thus obtained (yield=89%). [0050]
  • The analysis of the said product gave the results illustrated in Tables 2 and 3 below. [0051]
    TABLE 2
    Colour: Brown-yellow
    Solubility in distilled water: 10%
    pH (c = 1% in water): 7.84
  • [0052]
    TABLE 3
    Compounds Found (%) Expected (%)
    Flavone glycosides 18.9 18.69
    Ginkgolides 2.7 2.72
    Bilobalide 0.38 2.24
    Proanthocyanidins 1.7 3.09
    N-methylglucamine 32.6 33.3
  • EXAMPLE 3 Preparation of the N-methylglucamine/extract Complex (Weight Ratio 1:2.25)
  • The process was performed in a manner similar to that described in Example 2 above, except that extract 597 (10.42 g) of Table 1 was used and the amount of N-methylglucamine was 4.63 g. [0053]
  • 13.5 g of the desired product were thus obtained (yield=90%). [0054]
  • The analysis of the said product gave the results indicated in Tables 4 and 5. [0055]
    TABLE 4
    Colour: Brown-yellow
    Solubility in distilled water: 10%
    pH (c = 1% in water): 7.5
  • [0056]
    TABLE 5
    Compounds Found (%) Expected (%)
    Flavone glycosides 18.9 18.85
    Ginkgolides 4.41 5.02
    Bilobalide 0.54 2.26
    Proanthocyanidins 1.61 3.07
    N-methylglucamine 31.3 30.8
  • EXAMPLE 4 Preparation of the N-methylglucamine/extract Complex (Ratio 1:2.3)
  • A solution of extract 564a (10 g) of Table 1 in methanol (90 ml) was placed in a reactor equipped with a reflux condenser and a stirrer. The mixture was kept stirring at room temperature until the solid extract had fully dissolved. N-methylglucamine (4.35 g) dissolved in water (10 ml) was added to the solution. The mixture was stirred for 5 minutes and filtered. The thus obtained solution was concentrated under reduced pressure and at a temperature of not more than 50° C. The resulting solid residue was ground and brought to dryness under reduced pressure and at a temperature of not more than 70° C. [0057]
  • 13.22 g of the desired product were thus obtained (yield=92%). [0058]
  • The analysis of the said product gave the results shown in Tables 6 and 7. [0059]
    TABLE 6
    Colour: Brown-yellow
    Solubility in distilled water: 10%
    pH (c = 1 % in water): 9.58
  • [0060]
    TABLE 7
    Compounds Found (%) Expected (%)
    Flavone glycosides 17.1 19.7
    Ginkgolides 2.9 2.9
    Bilobalide 1.3 2.4
    Proanthocyanidins 1.78 3.23
    N-methylglucamine 30.0 30.3
  • EXAMPLE 5 Preparation of the N-methylglucamine/extract Complex (Ratio 1:2)
  • The process was performed in a manner similar to that described in Example 4 above, except that extract 632 (54 g) of Table 1 in 849 ml of methanol was used and the amount of N-methylglucamine added was 28 g. [0061]
  • 77 g of the desired product were thus obtained (yield=94%). The analysis of the said product gave the results shown in Tables 8 and 9. [0062]
    TABLE 8
    Colour: Brown-yellow
    Solubility in distilled water: 1%
    pH (c = 1% in water): 7.8
  • [0063]
    TABLE 9
    Compounds Found (%) Expected (%)
    Flavone glycosides 22.3 25.7
    Ginkgolides 4.13 4.15
    Bilobalide 0.1 0.15
    Proanthocyanidins 1.27 2.12
    N-methylglucamine 33.7 33.3
  • EXAMPLE 6 Preparation of the N-methylglucamine/extract Complex (Ratio 1:2)
  • The process was performed in a manner similar to that described in Example 4 above, except that extract 633 (10 g) of Table 1 in 150 ml of methanol was used and the amount of N-methylglucamine added was 5 g. [0064]
  • 13 g of the desired product were thus obtained (yield=86%). [0065]
  • The analysis of the said product gave the results shown in Tables 10 and 11. [0066]
    TABLE 10
    Colour: Brown-yellow
    Solubility in distilled water: 30%
    pH (c = 1 % in water): 7.8
  • [0067]
    TABLE 11
    Compounds Found (%) Expected (%)
    Flavone glycosides 27 27
    Ginkgolides 0.3 0.3
    Bilobalide 0 0.06
    Proanthocyanidins 1.2 2.32
    N-methylglucamine 33.2 33.3
  • EXAMPLE 7 Preparation of the N-methylglucamine/extract Complex (Ratio 1:2)
  • The process was performed in a manner similar to that described in Example 2 above, except that extract 640 (91.23 g) of Table 1 in 1370 ml of methanol was used and the amount of N-methylglucamine added was 45.61 g. [0068]
  • 123.2 g of the desired product were thus obtained (yield=90%). [0069]
  • The analysis of the said product gave the results shown in Tables 12 and 13. [0070]
    TABLE 12
    Colour: Brown-yellow
    Solubility in distilled water: 1%
    pH (c = 1% in water): 8.0
  • [0071]
    TABLE 13
    Compounds Found (%) Expected (%)
    Flavone glycosides 22.9 24.1
    Ginkgolides 5.96 6.0
    Bilobalide 0.17 0.1
    Proanthocyanidins 1.00 2.03
    N-methylglucamine 33.2 33.3

Claims (6)

1. A water-soluble complex of N-methylglucamine with an extract of Ginkgo biloba leaves.
2. A complex according to claim 1, characterized in that it has the following composition:
flavone glycosides: 15-30% (w/w),
ginkgolides: 0.1-7% (w/w),
bilobalide: 0-2% (w/w),
proanthocyanidins: 1-2% (w/w)
N-methylglucamine: 32-34% (w/w),
water-soluble inert plant matter: 25-51.9% (w/w).
3. A process for preparing a water-soluble complex of an extract of Ginkgo biloba leaves with N-methylglucamine, the said process comprising the steps of:
a) adding N-methylglucamine to an alcoholic solution of the said extract,
b) filtering the solid product obtained from step a), and
c) removing the solvent.
4. A process according to claim 3, characterized in that the composition of the said extract of Ginkgo biloba leaves is as follows:
flavone glycosides: 22-45% (w/w),
ginkgolides 0.1-12% (w/w),
bilobalide: 0.01-5% (w/w),
proanthocyanidins: 3-8% (w/w).
5. A process according to claim 3, characterized in that the amount of said extract in step a), on a dry-weight basis, is equal to about 1.5-3.0 times the weight of the N-methylglucamine.
6. A process according to claim 5, characterized in that the amount of the said extract in step a), on a dry-weight basis, is of about twice the weight of the N-methylglucamine.
US09/853,695 2000-06-16 2001-05-14 Water-soluble complex of an extract of Ginkgo biloba, process for the preparation thereof and composition comprising the same Expired - Fee Related US6447819B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00202088A EP1163908B1 (en) 2000-06-16 2000-06-16 Water-soluble complex of an extract of Ginkgo Bilboa, process for the preparation thereof and composition comprising the same
EP00202088 2000-06-16
EP00202088.1 2000-06-16

Publications (2)

Publication Number Publication Date
US20020012713A1 true US20020012713A1 (en) 2002-01-31
US6447819B2 US6447819B2 (en) 2002-09-10

Family

ID=8171637

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/853,695 Expired - Fee Related US6447819B2 (en) 2000-06-16 2001-05-14 Water-soluble complex of an extract of Ginkgo biloba, process for the preparation thereof and composition comprising the same

Country Status (8)

Country Link
US (1) US6447819B2 (en)
EP (1) EP1163908B1 (en)
JP (1) JP2002047191A (en)
AT (1) ATE265858T1 (en)
AU (1) AU4376801A (en)
DE (1) DE60010450T2 (en)
DK (1) DK1163908T3 (en)
ES (1) ES2219259T3 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823116B1 (en) * 2001-04-10 2004-11-19 Sod Conseils Rech Applic PROCESS FOR THE PREPARATION OF A HIGHLY ENRICHED GINKGO BILOBA LEAF EXTRACT IN ACTIVE INGREDIENTS
US20050054646A1 (en) * 2003-06-09 2005-03-10 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
WO2005105122A1 (en) * 2004-04-29 2005-11-10 Goetect Gmbh Ginkgo biloba extract and method for producing the same
CA2746652C (en) 2008-12-11 2018-03-06 Axcentua Pharmaceuticals Ab Crystalline forms of genistein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
FR2755015B1 (en) * 1996-10-25 1998-12-24 Sod Conseils Rech Applic USE OF A FLAVONOID EXTRACT OF GINKGO BILOBA SUBSTANTIALLY FREE OF TERPENES, IN THE ORAL FIELD, AND COMPOSITION CONTAINING SUCH EXTRACT
DE19829516B4 (en) 1998-07-02 2004-08-26 Dr. Willmar Schwabe Gmbh & Co. Kg Water-soluble native dry extract from Gingko biloba with a high content of terpenoids and flavone glycosides

Also Published As

Publication number Publication date
EP1163908A1 (en) 2001-12-19
ATE265858T1 (en) 2004-05-15
JP2002047191A (en) 2002-02-12
DK1163908T3 (en) 2004-07-12
ES2219259T3 (en) 2004-12-01
DE60010450D1 (en) 2004-06-09
US6447819B2 (en) 2002-09-10
DE60010450T2 (en) 2005-05-12
EP1163908B1 (en) 2004-05-06
AU4376801A (en) 2001-12-20

Similar Documents

Publication Publication Date Title
CA1337973C (en) Extracts of ginkgo biloba and their methods of preparation
US7776369B2 (en) Process for obtaining lignans
Bishop et al. Characterization of the condensation product of malvidin 3, 5-diglucoside and catechin
KR20080038127A (en) Cynara scolymus extracts, the use thereof and formulations containing them
US5637302A (en) Extracts of Ginkgo biloba and their methods of preparation
JPS6277390A (en) Manufacture of proanthocyanidin a2, medicinal composition and therapeutical use
EP0402925B1 (en) A method of isolating ginkgolides from the leaves of the ginkgo tree and purifying them
KR101676043B1 (en) Process for preparing a eucalyptus extract
FR2749303A1 (en) PROCESS FOR EXTRACTING CATECHIC POLYPHENOLS FROM POTENTIALLY OBTAINED EXTRACTS AND USE THEREOF
CA2375910C (en) Tanacetum parthenium extract
KR20010052636A (en) Extracts of Hypericum perforatum and formulations containing them
US6447819B2 (en) Water-soluble complex of an extract of Ginkgo biloba, process for the preparation thereof and composition comprising the same
JP4497566B2 (en) Aldose reductase inhibitors and novel saponins and novel sapogenols
KR102297600B1 (en) A preparation method for extract of Ginkgo biloba leaf having increased contents of quercetin and kaempferol
JPH01175978A (en) Production of crude catechin compound
JP4772190B2 (en) Skin lightening agent
JPH07196640A (en) Production and use of 4-hydroxy-5-methyl-3(2h)-franone
NL1009437C2 (en) Extraction process.
RU2088256C1 (en) Agent for complex sickness therapy and a method of its preparing
KR940002796B1 (en) Method of isolation and purification of ginkgolide of ginkgo
KR100197353B1 (en) Novel process for preparation of gingko extract
KR900005318B1 (en) Process for purifying physiological active materials from ginko tree leaves
KR900005319B1 (en) Process for purifying physiological active materials from ginko tree leaves
JPH07110213B2 (en) Food material
RU2236863C1 (en) Method for preparing preparation flavitex

Legal Events

Date Code Title Description
AS Assignment

Owner name: LINNEA SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PARACCHINI, SILVANO;REEL/FRAME:011988/0391

Effective date: 20010503

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100910